Effect of entecavir combined with fuzheng huayu capsule on inflammatory factors and fibrosis index in patients with chronic hepatitis b cirrhosis
10.3969/j.issn.1005-1678.2017.10.015
- VernacularTitle:恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响
- Author:
Yan YANG
1
;
qi Zhong SUO
Author Information
1. 宁夏回族自治区人民医院 感染科
- Keywords:
entecavir;
fuzheng huayu capsule;
chronic hepatitis b;
decompensation;
cirrhosis;
inflammatory factor;
fibrosis index
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):40-41,44
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of entecavir combined with Fuzheng Huayu capsule in patients with chronic hepatitis B cirrhosis. Methods A total of 102 decompensated patients with chronic hepatitis B cirrhosis were enrolled in our hospital from May 2015 to May 2017. The patients were divided into study group and control group by random number method. The patients were treated with routine symptom and liver Treatment group, based on this line of entecavir treatment, the study group in the conventional therapy based on entecavir combined with Fuzheng Huayu capsule treatment, compared the two groups of patients with HBV DNA negative rate, inflammatory factors, fibrosis indicators and liver function indicators. Results However, the improvement of inflammatory factors, fibrosis indexes and liver function indexes in the study group was more significant than that in the control group, and the difference was significant, but there was no significant difference between the two groups There was statistical significance (P<0.05). Conclusion The efficacy of entecavir combined with Fuzheng Huayu capsule in patients with chronic hepatitis B liver cirrhosis is accurate and worthy of clinical application in clinical practice.
